Connect with us

News

Intel venture arm’s China tech stakes raises alarm in Washington

Published

on

Intel venture arm’s China tech stakes raises alarm in Washington

Intel’s venture capital arm has emerged as one of the most active foreign investors in Chinese artificial intelligence and semiconductor start-ups, at a time the $147bn chipmaker receives billions of dollars from Washington to fund a technological arms race with Beijing.

Intel Capital owns stakes in 43 China-based technology start-ups, according to an FT analysis of its portfolio. Since the venture fund was launched in the early 1990s, it has invested in more than 120 Chinese groups, according to data provider Crunchbase.

The fund, which invests off the chipmaker’s balance sheet, has continued to back fledgling Chinese companies in the past year, even as many of its American peers exited the market under pressure from US authorities.

In February Intel Capital invested in a $20mn fundraising round by Shenzhen-based AI-Link, a 5G and cloud infrastructure platform, and last year led a $91mn round for Shanghai-headquartered North Ocean Photonics, a maker of micro-optics hardware.

Rising geopolitical tensions between Washington and Beijing have led to greater scrutiny of private investment flows between the two economic powers as they jostle for technological and military supremacy.

Advertisement

In June, the Biden administration unveiled rules to curb US financing for Chinese technology that could have military purposes, such as AI, quantum computing and semiconductors. The regulations are expected to be finalised this year.

Intel Capital’s “investments were poster children that helped build consensus for the outbound restrictions”, according to one person familiar with the Biden administration’s thinking on the new rules.

Its current investments in China include around 16 AI start-ups and 15 in the semiconductor industry, as well as companies developing cloud services, electric vehicles, telecoms, virtual reality systems and batteries.

Intel Capital may be forced to divest from some companies once the US regulations take effect, though the US Treasury is examining whether to include some exemptions for some venture capital transactions.

However, the US group has slowed down its dealmaking in China over the past 18 months, according to data provider ITjuzi, completing just three deals since the start of 2023. Investment controls and a slowdown in the Chinese economy, as well as lasting repercussions from Beijing’s crackdown on tech companies, have hit start-up valuations and viability.

Advertisement

A report by a US House China committee on the Chinese Communist party in February said that American venture capital firms had invested billions of dollars into companies that were fuelling China’s “military, surveillance state and Uyghur genocide”. This includes funnelling $1.9bn into AI companies and a further $1.2bn into semiconductors.

The report singled out five US venture firms — Sequoia, GGV, GSR Ventures, Qualcomm Ventures and Walden International — but did not mention Intel Capital, despite the fund becoming one of the largest US investors in China after the departure of some of its rivals.

Intel Capital is “way more active” than Qualcomm’s venture arm in China, said the head of a large US fund with a long history of doing business in China. “Intel is active in everything.”

John Moolenaar, Republican head of the House China committee, said the case highlighted the need for tighter regulation.

“The Chinese Communist party remembers the old communist slogan that ‘the capitalists will sell us the rope with which we will hang them’,” said Moolenaar. “We need strong outbound capital restrictions to prevent American firms from investing in companies closely tied to the CCP’s armed forces.”

Advertisement

Intel Capital declined to comment.

Sequoia Capital and GGV Capital, two of the largest US venture investors in China, spun out their Chinese businesses last year amid the mounting political pressure. Qualcomm, Walden and GSR also continue to invest in Chinese start-ups.

In March Intel received about $20bn in grants and loans from the US to fund an expansion of its semiconductor factories, the largest award from the government’s 2022 Chips and Science Act designed to enhance the domestic chip industry. The package will support more than $100bn in US investments from Intel for advanced chipmaking facilities, including building mega-plants in Ohio and Arizona.

You are seeing a snapshot of an interactive graphic. This is most likely due to being offline or JavaScript being disabled in your browser.

Nasdaq-listed Intel has a large China business, where it employs around 12,000 people and accounted for 27 per cent of global revenue in 2023.

Advertisement

Chinese multinational Lenovo is one of the three largest customers of its chips, alongside Dell and HP, generating 11 per cent of global revenue. Last month, Intel’s China arm acquired a 3 per cent stake in Shenzhen telecoms equipment maker Luxshare.

Intel Capital’s China business is run by Tianlin Wang, a life-long Intel employee and head of the unit since 2017. It has six other investment directors in the country. Globally, Intel Capital has invested more than $20bn since the early 1990s and is led by Anthony Lin in San Francisco.

Intel Capital has participated in Chinese start-up deals worth a total $1.4bn since 2015, according to data from PitchBook. That figure relates to the total value of the deals rather than Intel Capital’s individual contribution, which the firm does not make public.

As early as 2014, Intel Capital announced it had invested $670mn in more than 110 Chinese technology companies, and in 2015 alone it gave $67mn to eight Chinese tech companies. Since then, Intel Capital has not publicly revealed the scale of its investments in China.

A report in February 2023 by the US Center for Security and Emerging Technology, a DC think-tank, into the national security risks associated with US investment in Chinese AI companies, found that Intel Capital participated in 11 deals for such companies between 2015 and 2021. A person close to Intel said there were only four AI deals during this time.

Advertisement

In some cases, the US fund obtained a board seat, such as at Horizon Robotics, a chipmaker, and Eeasy Tech, which designs AI chips for facial recognition and that was also backed by the Zhuhai provincial government.

“Intel Capital’s investments in Chinese AI firms have led to the formation of strategic collaborations that could benefit the Chinese companies in a way that complements Chinese government strategies,” that report said.

In one case, Intel Capital helped fund the creation of a Chinese company that was later sanctioned by the US. The fund was one of the earliest investors in AI voice recognition group iFlytek, acquiring a 3 per cent stake in 2002 before selling the shareholding two years later. The company was one of six Chinese companies banned by the US in 2019 for their roles in alleged human rights abuses in Xinjiang.

“The fear of missing out in the AI era has created a sense of urgency for Intel Capital,” said the head of a rival Chinese venture firm that has co-invested alongside them. “Intel is under such fierce competition in AI in the US, they can’t afford to be left behind, so they have to look around the world for where to deploy money into AI and China is one of the very few options.”

Advertisement

News

Louisiana Sen. Bill Cassidy loses in Republican primary, does not advance to runoff

Published

on

Louisiana Sen. Bill Cassidy loses in Republican primary, does not advance to runoff

One observer of the current Senate race in Louisiana noted that Sen. Bill Cassidy could lose his reelection bid.

Annie Flanagan for NPR


hide caption

toggle caption

Advertisement

Annie Flanagan for NPR

Sen. Bill Cassidy lost Saturday’s Louisiana Republican primary according to a race call by the Associated Press.

Cassidy, who served two terms in the Senate, was one of seven Republican senators who voted to convict President Trump after the January 6th insurrection at the Capitol. That vote put him at odds with Trump and his MAGA coalition, ultimately leading Trump to push Rep. Julia Letlow to run against Cassidy.

Cassidy’s bid for a third term was viewed as a test of Trump’s grip on the party–and of what voters want from their representatives in Washington. The primary pitted Cassidy, a veteran lawmaker, former physician and chair of the powerful Senate health committee, against Letlow, a political newcomer and a millennial MAGA loyalist.

Advertisement
A detailed view of a hat that reads, Run Julia Run, is seen at a campaign event for Rep. Julia Letlow (R-LA) on May 6, 2026 in Franklinton, Louisiana.

A detailed view of a hat that reads, Run Julia Run, is seen at a campaign event for Rep. Julia Letlow (R-LA) on May 6, 2026 in Franklinton, Louisiana.

Tyler Kaufman/Getty Images


hide caption

toggle caption

Tyler Kaufman/Getty Images

Advertisement

A former college administrator, Letlow won a special election in 2021 for the House seat her late husband, Luke, was set to assume before he died from COVID in 2020.

In Congress, Letlow sponsored a bill to collect oral histories from the pandemic and has focused on education and children. She introduced the “Parents Bill of Rights Act,” which would allow parents to review classroom materials like library books and require schools to notify parents if their child requests different pronouns, locker rooms or sports teams.

She also serves on the powerful appropriations committee and has embraced Trump’s agenda.

Advertisement

Letlow, who came first in Saturday’s primary, will face Louisiana state Treasurer John Fleming in the runoff on June 27. Cassidy came in third.

The election result is a victory for President Trump who has put Republican loyalty to the test on the ballot so far this year in Indiana state senate primaries and in Cassidy’s race.

Another major test of Trump’s influence comes in Kentucky’s primary on Tuesday when Republican Rep. Thomas Massie, who has found himself at odds with the president, faces a challenger endorsed by Trump.

Continue Reading

News

Brass bands in Beijing make way for sticker shock at home as Trump returns to escalating inflation

Published

on

Brass bands in Beijing make way for sticker shock at home as Trump returns to escalating inflation

WASHINGTON (AP) — President Donald Trump returned from the spectacle of a Chinese state visit to a less than welcoming U.S. economy — with the military band and garden tour in Beijing giving way to pressure over how to fix America’s escalating inflation rate.

Consumer inflation in the United States increased to 3.8% annually in April, higher than what he inherited as the Iran war and the Republican president’s own tariffs have pushed up prices. Inflation is now outpacing wage gains and effectively making workers poorer. The Cleveland Federal Reserve estimates that annual inflation could reach 4.2% in May as the war has kept oil and gasoline prices high.

Trump’s time with Chinese leader Xi Jinping appears unlikely to help the U.S. economy much, despite Trump’s claims of coming trade deals. The trip occurred as many people are voting in primaries leading into the November general election while having to absorb the rising costs of gasoline, groceries, utility bills, jewelry, women’s clothing, airplane tickets and delivery services. Democrats see the moment as a political opportunity.

“He’s returning to a dumpster fire,” said Lindsay Owens, executive director of Groundwork Collaborative, a liberal think tank focused on economic issues. “The president will not have the faith and confidence of the American people — the economy is their top issue and the president is saying, ‘You’re on your own.’”

The president’s trip to Beijing and his recent comments that indicated a tone-deafness to voters’ concerns about rising prices have suggested his focus is not on the American public and have undermined Republicans who had intended to campaign on last year’s tax cuts as helping families.

Advertisement

Trump described the trip as a victory, saying on social media that Xi “congratulated me on so many tremendous successes,” as the U.S. president has praised their relationship.

Trump told reporters that Boeing would be selling 200 aircraft — and maybe even 750 “if they do a good job” — to the Chinese. He said American farmers would be “very happy” because China would be “buying billions of dollars of soybeans.”

“We had an amazing time,” Trump said as he flew home on Air Force One, and told Fox News’ Bret Baier in an interview that gasoline prices were just some “short-term pain” and would “drop like a rock” once the war ends.

Inflationary pain is not a factor in how Trump handles Iran

Trump departed from the White House for China by saying the negotiations over the Iran war depended on stopping Tehran from developing nuclear weapons. “I don’t think about Americans’ financial situation. I don’t think about anybody. I think about one thing: We cannot let Iran have a nuclear weapon,” Trump said.

That remark prompted blowback because it suggested to some that Trump cared more about challenging Iran than fighting inflation at home. Trump defended his words, telling Fox News: “That’s a perfect statement. I’d make it again.”

Advertisement

The White House has since stressed that Trump is focused on inflation.

Asked later about the president’s words, Vice President JD Vance said there had been a “misrepresentation” of the remarks. White House spokesman Kush Desai said the “administration remains laser-focused on delivering growth and affordability on the homefront” while indicating actions would be taken on grocery prices.

But as Trump appeared alongside Xi, new reports back home showed inflation rising for businesses and interest rates climbing on U.S. government debt.

His comments that Boeing would sell 200 jets to China caused the company’s stock price to fall because investors had expected a larger number. There was little concrete information offered about any trade agreements reached during the summit, including Chinese purchases of U.S. exports such as liquefied natural gas and beef.

“Foreign policy wins can matter politically, but only if voters feel stability and affordability in their daily lives,” said Brittany Martinez, a former Republican congressional aide who is the executive director of Principles First, a center-right advocacy group focused on democracy issues.

Advertisement

“Midterms are almost always a referendum on cost of living and public frustration, and Republicans are not immune from the same inflation and affordability pressures that hurt Democrats in recent cycles,” she added.

Democrats see Trump as vulnerable

Democratic lawmakers are seizing on Trump’s comments before his trip as proof of his indifference to lowering costs. There is potential staying power of his remarks as Americans head into Memorial Day weekend facing rising prices for the hamburgers and hot dogs to be grilled.

“What Americans do not see is any sympathy, any support, or any plan from Trump and congressional Republicans to lower costs – in fact, they see the opposite,” Senate Democratic leader Chuck Schumer of New York said Thursday.

Vance faulted the Biden administration for the inflation problem even though the inflation rate is now higher than it was when Trump returned to the White House in January 2025 with a specific mandate to fix it.

“The inflation number last month was not great,” Vance said Wednesday, but he then stressed, “We’re not seeing anything like what we saw under the Biden administration.”

Advertisement

Inflation peaked at 9.1% in June 2022 under Biden, a Democrat. By the time Trump took the oath of office, it was a far more modest 3%.

Trump’s inflation challenge could get harder

The data tells a different story as higher inflation is spreading into the cost of servicing the national debt.

Over the past week, the interest rate charged on 10-year U.S. government debt jumped from 4.36% to 4.6%, an increase that implies higher costs for auto loans and mortgages.

“My fear is that the layers of supply shocks that are affecting the U.S. economy will only further feed into inflationary pressures,” said Gregory Daco, chief economist at EY-Parthenon.

Daco noted that last year’s tariff increases were now translating into higher clothing prices. With the Supreme Court ruling against Trump’s ability to impose tariffs by declaring an economic emergency, his administration is preparing a new set of import taxes for this summer.

Advertisement

Daco stressed that there have been a series of supply shocks. First, tariffs cut into the supply of imports. In addition, Trump’s immigration crackdown cut into the supply of foreign-born workers. Now, the effective closure of the Strait of Hormuz has cut off the vital waterway used to ship 20% of global oil supplies.

“We’re seeing an erosion of growth,” Daco said.

Advertisement
Continue Reading

News

Top Drug Regulator Is Fired From the F.D.A.

Published

on

Top Drug Regulator Is Fired From the F.D.A.

Dr. Tracy Beth Hoeg, the Food and Drug Administration’s top drug regulator, said she was fired from the agency Friday after she declined to resign.

She said she did not know who had ordered her firing or why, nor whether Health Secretary Robert F. Kennedy Jr. knew of her fate. The Department of Health and Human Services did not immediately respond to a request for comment.

The departure reflected the upheaval at the F.D.A., days after the resignation of Dr. Marty Makary, the agency commissioner. Dr. Makary had become a lightning rod for critics of the agency’s decisions to reject applications for rare disease drugs and to delay a report meant to supply damaging evidence about the abortion drug mifepristone. He also spent months before his departure pushing back on the White House’s requests for him to approve more flavored vapes, the reason he ultimately cited for leaving.

Dr. Hoeg’s hiring had startled public health leaders who were familiar with her track record as a vaccine skeptic, and she played a leading role in some of the agency’s most divisive efforts during her tenure. She worked on a report that purportedly linked the deaths of children and young adults to Covid vaccines, a dossier the agency has not released publicly. She was also the co-author of a document describing Mr. Kennedy’s decision to pare the recommendations for 17 childhood vaccines down to 11.

But in an interview on Friday, Dr. Hoeg said she “stuck with the science.”

Advertisement

“I am incredibly proud of the work we were doing,” Dr. Hoeg said, adding, “I’m glad that we didn’t give in to any pressures to approve drugs when it wasn’t appropriate.”

As the director of the agency’s Center for Drug Evaluation and Research, she was a political appointee in a role that had been previously occupied by career officials. An epidemiologist who was trained in the United States and Denmark, she worked on efforts to analyze drug safety and on a panel to discuss the use of serotonin reuptake inhibitors, the most widely prescribed class of antidepressants, during pregnancy. She also worked on efforts to reduce animal testing and was the agency’s liaison to an influential vaccine committee.

She made sure that her teams approved drugs only when the risk-benefit balance was favorable, she said.

The firing worsens the leadership vacuum at the F.D.A. and other agencies, with temporary leaders filling the role of commissioner, food chief and the head of the biologics center, which oversees vaccines and gene therapies. The roles of surgeon general and director of the Centers for Disease Control and Prevention are also unfilled.

Advertisement
Continue Reading
Advertisement

Trending